Another Iatrogenic Illness Unveiled
The term “iatrogenic” means doctor, drug or surgery-caused disease. It is a taboo subject in America today.
I don’t know how many of my readers listen to John Gilbert’s daily talk show on Duluth’s local KDAL radio station (610 AM). John is the journalist that writes the best sports-related columns that I have ever read. Those sports columns appears every week in the Duluth Reader, which is where my Duty to Warn column is published; so we are colleagues. John is a wonderful radio interviewer who occasionally invites me to appear on his “The John Gilbert Show” when medical issues arise. The show is on every weekday morning from 9 – 11 am. It is archived at
This morning (8-16-16), just before I was about to begin writing this week’s column, John called and asked me to appear on the show to give my medical opinion about the dramatic recovery of dementia victim Kris Kristofferson, the legendary singer/song-writer who had been erroneously diagnosed with incurable late-stage Alzheimer’s dementia (of unknown origin).
John had seen Kristofferson perform onstage with Merle Haggard a year or two ago when he was obviously seriously demented (although still able to remember the lyrics of his own songs). And then, just recently, John again saw Kristofferson perform in a solo concert when his dementia symptoms had completely disappeared! Reader publisher and editor Bob Boone graciously provided the $70 dollar tickets for John and his wife Joan.
Apparently Kristofferson (right) had been mis-diagnosed with Alzheimer’s dementia about three years ago, which started more than one medical misadventure for he and his neurologists involving neurotoxic medication trials with drugs. Those drugs that Kristofferson was treated with had been approved by the FDA on the basis of a couple of short-term trials involving only a few hundred so-called “Alzheimer’s Dementia” patients. The results that were submitted to the FDA showed only minimal improvement (albeit “statistically significant”), but only in mild to moderate dementia. Thus treating severely demented patients with those drugs was not FDA-approved (“off-label”).